165 related articles for article (PubMed ID: 20638295)
1. GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain.
Yao CH; Lin KJ; Weng CC; Hsiao IT; Ting YS; Yen TC; Jan TR; Skovronsky D; Kung MP; Wey SP
Appl Radiat Isot; 2010 Dec; 68(12):2293-7. PubMed ID: 20638295
[TBL] [Abstract][Full Text] [Related]
2. Validation of an (18)F-labeled biphenylalkyne as a positron emission tomography imaging agent for beta-amyloid plaques.
Wey SP; Weng CC; Lin KJ; Yao CH; Yen TC; Kung HF; Skovronsky D; Kung MP
Nucl Med Biol; 2009 May; 36(4):411-7. PubMed ID: 19423009
[TBL] [Abstract][Full Text] [Related]
3. Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging agent for Alzheimer's disease.
Liu Y; Zhu L; Plössl K; Choi SR; Qiao H; Sun X; Li S; Zha Z; Kung HF
Nucl Med Biol; 2010 Nov; 37(8):917-25. PubMed ID: 21055622
[TBL] [Abstract][Full Text] [Related]
4. Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.
Lister-James J; Pontecorvo MJ; Clark C; Joshi AD; Mintun MA; Zhang W; Lim N; Zhuang Z; Golding G; Choi SR; Benedum TE; Kennedy P; Hefti F; Carpenter AP; Kung HF; Skovronsky DM
Semin Nucl Med; 2011 Jul; 41(4):300-4. PubMed ID: 21624563
[TBL] [Abstract][Full Text] [Related]
5. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study.
Lin KJ; Hsu WC; Hsiao IT; Wey SP; Jin LW; Skovronsky D; Wai YY; Chang HP; Lo CW; Yao CH; Yen TC; Kung MP
Nucl Med Biol; 2010 May; 37(4):497-508. PubMed ID: 20447562
[TBL] [Abstract][Full Text] [Related]
6. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.
Choi SR; Schneider JA; Bennett DA; Beach TG; Bedell BJ; Zehntner SP; Krautkramer MJ; Kung HF; Skovronsky DM; Hefti F; Clark CM
Alzheimer Dis Assoc Disord; 2012; 26(1):8-16. PubMed ID: 22354138
[TBL] [Abstract][Full Text] [Related]
7. Preparation and stability of ethanol-free solution of [18F]florbetapir ([18F]AV-45) for positron emission tomography amyloid imaging.
Hayashi K; Tachibana A; Tazawa S; Mizukawa Y; Osaki K; Morimoto Y; Zochi R; Kurahashi M; Aki H; Takahashi K
J Labelled Comp Radiopharm; 2013 May; 56(5):295-300. PubMed ID: 24285374
[TBL] [Abstract][Full Text] [Related]
8. Technical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir.
Trembath L; Newell M; Devous MD
J Nucl Med Technol; 2015 Sep; 43(3):175-84. PubMed ID: 26271806
[TBL] [Abstract][Full Text] [Related]
9. [Amyloid PET imaging with [18F]AV-45].
Tateno A; Okubo Y
Nihon Rinsho; 2011 Oct; 69 Suppl 8():561-4. PubMed ID: 22787851
[No Abstract] [Full Text] [Related]
10. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.
Okamura N; Yanai K
IDrugs; 2010 Dec; 13(12):890-9. PubMed ID: 21154149
[TBL] [Abstract][Full Text] [Related]
11. Florbetapir F 18 for brain imaging of β-amyloid plaques.
Romano M; Buratti E
Drugs Today (Barc); 2013 Mar; 49(3):181-93. PubMed ID: 23527322
[TBL] [Abstract][Full Text] [Related]
12. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.
Choi SR; Golding G; Zhuang Z; Zhang W; Lim N; Hefti F; Benedum TE; Kilbourn MR; Skovronsky D; Kung HF
J Nucl Med; 2009 Nov; 50(11):1887-94. PubMed ID: 19837759
[TBL] [Abstract][Full Text] [Related]
13. Amyloid-β positron emission tomography in the diagnostic evaluation of alzheimer disease: summary of primary findings and conclusions.
Pearson SD; Ollendorf DA; Colby JA
JAMA Intern Med; 2014 Jan; 174(1):133-4. PubMed ID: 24081022
[No Abstract] [Full Text] [Related]
14. Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir.
Hornberger J; Bae J; Watson I; Johnston J; Happich M
Curr Med Res Opin; 2017 Apr; 33(4):675-685. PubMed ID: 28035842
[TBL] [Abstract][Full Text] [Related]
15. Current status of PET-imaging probes of β-amyloid plaques.
Koo J; Byun Y
Arch Pharm Res; 2013 Oct; 36(10):1178-84. PubMed ID: 23812777
[TBL] [Abstract][Full Text] [Related]
16. Brain amyloid imaging--FDA approval of florbetapir F18 injection.
Yang L; Rieves D; Ganley C
N Engl J Med; 2012 Sep; 367(10):885-7. PubMed ID: 22931256
[No Abstract] [Full Text] [Related]
17. Quantification of [
Golla SS; Verfaillie SC; Boellaard R; Adriaanse SM; Zwan MD; Schuit RC; Timmers T; Groot C; Schober P; Scheltens P; van der Flier WM; Windhorst AD; van Berckel BN; Lammertsma AA
J Cereb Blood Flow Metab; 2019 Nov; 39(11):2172-2180. PubMed ID: 29897009
[TBL] [Abstract][Full Text] [Related]
18. Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.
Cortes-Blanco A; Prieto-Yerro C; Martinez-Lazaro R; Zamora J; Jiménez-Huete A; Haberkamp M; Pohly J; Enzmann H; Zinserling J; Strassmann V; Broich K
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S395-9. PubMed ID: 24418060
[TBL] [Abstract][Full Text] [Related]
19. An improved preparation of [
Zhang L; Zhang A; Yao X; Zhang Y; Liu F; Hong H; Zha Z; Liu Y; Wu Z; Qiao J; Zhu L; Kung HF
J Labelled Comp Radiopharm; 2020 Mar; 63(3):108-118. PubMed ID: 31697847
[TBL] [Abstract][Full Text] [Related]
20. Automated synthesis of [18F]Florbetaben as Alzheimer's disease imaging agent based on a synthesis module system.
Wang H; Guo X; Jiang S; Tang G
Appl Radiat Isot; 2013 Jan; 71(1):41-6. PubMed ID: 23085550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
